Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01475097 · ClinicalTrials.gov registry record · Phase 4
Comparing Patient Comfort and Safety Between Iodixanol and Iopamidol in Patients Undergoing Peripheral Arteriography
A Phase 4 study of Drug Safety, sponsored by GE Healthcare.
- Completed
- Registry status
- Phase 4
- Development phase
- 255
- Enrollment target
- 1
- Study location
NCT01475097 is a Phase 4 study of Drug Safety that has completed, run by GE Healthcare. The registered enrollment target is 255 participants, above the 40-participant average among 4 other Drug Safety trials with a reported enrollment target (538% higher). The trial reports 1 study location across 1 state.
The verdict
NCT01475097, a Phase 4 study of Drug Safety, has completed, sponsored by GE Healthcare.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 255 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate and compare overall patient comfort profile between an Iso-osmolar contrast media (IOCM), iodixanol 320 mg I/mL, and a Low-osmolar contrast media (LOCM), iopamidol 370 mg I/mL in patients undergoing arteriography of peripheral arteries.
Conditions Studied
Interventions
- DRUG Iopamidol
- DRUG Iodixanol
Study Locations (1)
New Jersey
- GE Healthcare - Princeton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 255 participants |
| Start Date | 2011-10 |
| Est. Completion | 2013-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01475097
The ClinicalTrials.gov registry entry for NCT01475097 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 255 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 40-participant average among 4 other Drug Safety trials with a reported enrollment target (538% higher). The listed sponsor is GE Healthcare, which has 99 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Drug Safety appearing as the primary indexed condition, and to 2 interventions - of which Iopamidol is the first listed.
NCT01475097 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT01475097 about?
NCT01475097 is a clinical study titled "Comparing Patient Comfort and Safety Between Iodixanol and Iopamidol in Patients Undergoing Peripheral Arteriography". The purpose of this study is to evaluate and compare overall patient comfort profile between an Iso-osmolar contrast media (IOCM), iodixanol 320 mg I/mL, and a Low-osmolar contrast media (LOCM), iopamidol 370 mg I/mL in patients undergoing arteriography of peripheral arteries.
What is the current status of trial NCT01475097?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 255 participants. The study started on 2011-10. Estimated completion is 2013-02.
What conditions does trial NCT01475097 study?
This clinical trial studies the following conditions: Drug Safety.
What interventions are being tested in trial NCT01475097?
The interventions under investigation include: Iopamidol (DRUG), Iodixanol (DRUG).
Who is sponsoring clinical trial NCT01475097?
This trial is sponsored by GE Healthcare, which has 99 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01475097 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Drug Safety
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Reducing and Removing Hyaluronic Acid Filler With Hyaluronidase
ACTIVE NOT RECRUITING · Early Phase 1
-
Safety and Pharmacokinetics Study of CARD-024 in Healthy Subjects
COMPLETED · Phase 1
-
Clinical Safety of a Novel Milk Protein Peptide
COMPLETED · Phase 1
-
Ascending Multiple-Dose Study to Evaluate VIA-3196 in Healthy Subjects
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.